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https://doi.org/10.1016/j.molcel.2021.03.019SUMMARYCancer cells adapt their metabolism to support elevated energetic and anabolic demands of proliferation.
Folate-dependent one-carbon metabolism is a critical metabolic process underpinning cellular proliferation
supplying carbons for the synthesis of nucleotides incorporated into DNA and RNA. Recent research has
focused on the nutrients that supply one-carbons to the folate cycle, particularly serine. Tryptophan is a theo-
retical source of one-carbon units through metabolism by IDO1, an enzyme intensively investigated in the
context of tumor immune evasion. Using in vitro and in vivo pancreatic cancer models, we show that IDO1
expression is highly context dependent, influenced by attachment-independent growth and the canonical
activator IFNg. In IDO1-expressing cancer cells, tryptophan is a bona fide one-carbon donor for purine nucle-
otide synthesis in vitro and in vivo. Furthermore, we show that cancer cells release tryptophan-derived
formate, which can be used by pancreatic stellate cells to support purine nucleotide synthesis.INTRODUCTION
Cancer cells adapt their metabolism to support proliferation and
survival (Hanahan and Weinberg, 2011). A better understanding
of cancer-specificmetabolic changes is key for improved cancer
treatment. One-carbon metabolism has been a target of cancer
therapy since the 1940s (Newman and Maddocks, 2017a,
2017b) and encompasses a collection of metabolic pathways
that enable cells to generate and use molecules containing sin-
gle carbons. One-carbon units are carried and activated for
use by tetrahydrofolates (THFs), derived from dietary folate.
Cells require one-carbon units to support nucleotide synthesis,
methylation reactions, and reductive metabolism.
The non-essential amino acid serine is considered the
predominant source of one-carbon units (Ducker et al., 2016;
Labuschagne et al., 2014). Serine is obtained either by de novo
synthesis via the serine synthesis pathway (SSP) or by uptake
from the extracellular environment. Some cancer cells display
increased SSP enzyme expression (Locasale et al., 2011; Posse-
mato et al., 2011; Sullivan et al., 2019b), whereas others rely
predominantly on serine uptake. Strategies to limit serine avail-
ability, either by the inhibition of serine synthesis (Pacold et al.,
2016; Possemato et al., 2011) or the dietary restriction of serine
(Baksh et al., 2020; LeBoeuf et al., 2020; Maddocks et al., 2013,Molecular Cell 81, 1–
This is an open access article und2017; Muthusamy et al., 2020), have shown promise as an anti-
cancer therapy using preclinical models. Serine hydroxymethyl-
transferases (SHMT1 and SHMT2) directly catalyze the conver-
sion of serine into glycine and the release of a one-carbon, which
enters the THF cycle. Targeted strategies to inhibit SHMT en-
zymes and the downstream THF cycle enzymes controlling the
utilization of serine-derived carbons have had limited success
in inhibiting cancer cell proliferation, chiefly due to metabolic
plasticity (Ducker et al., 2016).
Besides serine, the amino acids glycine, histidine, and trypto-
phan are potential one-carbon donors. Glycine can theoretically
provide one-carbon units through the glycine cleavage system
(GCS) (Jain et al., 2012), although the relevance of this in cancer
cells is unclear (Kim et al., 2015; Labuschagne et al., 2014). His-
tidine catabolism can also yield one-carbon units and can sensi-
tize cancer cells to anti-folate treatment by decreasing free THF
pools (Kanarek et al., 2018). Improved understanding of how
cancer cells obtain and use one-carbon units can therefore offer
new opportunities to improve anti-cancer therapy.
As an essential amino acid, tryptophan is critical for protein
synthesis and is a precursor for 5-hydroxytryptamine and ky-
nurenine production. In the kynurenine pathway, the initial and
rate-limiting step is the conversion of tryptophan to formyl-ky-
nurenine. Three enzymes are capable of catalyzing this13, June 3, 2021 ª 2021 The Authors. Published by Elsevier Inc. 1
er the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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expression levels and limited tissue specificity (Hornyák et al.,
2018). Therefore, IDO1 is considered the predominant form
and has been widely studied, including its activation by the
immune cytokine interferon g (IFNg) (Katz et al., 2008; Prender-
gast, 2008). Formyl-kynurenine spontaneously forms kynure-
nine, with the release of a molecule of formate. Formate can
enter the one-carbon cycle by directly reacting with THF, and
it is via this pathway that tryptophan can serve as a one-carbon
donor. However, it is unknown whether this process is active in
cancer cells.
IDO1-dependent tryptophan metabolism in cancer has been
investigated predominantly in the context of immune regulation
and immunotherapy. High IDO1 expression is associated with
poor prognosis in a range of cancers (Yu et al., 2018). IDO1 ac-
tivity depletes tryptophan and increases kynurenine in the tumor
microenvironment, causing a range of effects on immune cells.
Tryptophan depletion decreases tumor-infiltrating T cell activity,
possibly due to GCN2 kinase activity (Munn et al., 2005),
although this has been disputed (Sonner et al., 2016). Kynurenine
itself decreases effector T cell proliferation (Terness et al., 2002)
and supports the differentiation of immunosuppressive T-regula-
tory cells through the binding of the aryl hydrocarbon receptor
(Mezrich et al., 2010). Overall, these tumor microenvironmental
effects are reported to provide an immunologically permissive
environment for tumor growth. Reflecting the recent success
of immunotherapy agents, IDO1 inhibitors such as epacadostat
(Liu et al., 2010) have entered trials (clinical trials.gov returns 60
trials with epacadostat at the time of writing). However, several
trials have returned disappointing results (Garber, 2018), stimu-
lating efforts to better understand the functions of IDO1 and
improve the efficacy of these inhibitors.
Despite a rich literature addressing how IDO1-driven trypto-
phan metabolism affects the behavior of immune cells, knowl-
edge of how this pathway influences metabolic pathways within
cancer cells themselves is largely absent. This is surprising,
given that the kynurenine pathway has several metabolic outputs
with widely known importance for cancer metabolism: reactive
oxygen species (superoxide), one-carbonmetabolism, synthesis
of NAD(P)+, synthesis of alanine, and entry of carbons (via a-ke-
toadipate) into the tricarboxylic acid (TCA) cycle.
In the present study, we sought to investigate the metabolic
consequences of IDO1-driven tryptophan metabolism in the
context of pancreatic ductal adenocarcinoma (PDAC). PDAC tu-
mors are extremely aggressive, with poor clinical outcomes.
Characteristically, these tumors exhibit hypovascularization
and deranged metabolism and contain a large proportion of
complex stroma. Non-cancerous stromal stellate cells can sup-
port tumor cell metabolism through the provision of nutrients
such as alanine (Sousa et al., 2016). Unlike other tumor models,
PDAC-bearing (KPC) mice are unresponsive to serine restriction
(Maddocks et al., 2017). There is evidence that this may be due
to the enhanced de novo synthesis of serine (Maddocks et al.,
2017), but an additional contributing factor may be an ability to
use alternative one-carbon sources such as tryptophan. Intrigu-
ingly, it has recently been reported that tryptophan is one of the
most depleted nutrients in interstitial fluid within KPC PDAC tu-
mors (Sullivan et al., 2019a).2 Molecular Cell 81, 1–13, June 3, 2021Analysis of public data shows that several tumor types,
including pancreatic cancer, have high-IDO1-expressing sub-
sets, and we show that IDO1 is expressed in genetically engi-
neered mouse models for PDAC. We find that IDO1 expression
is not well represented in standard in vitro cell culture conditions,
but can be induced by the canonical activator IFNg or by culture
in low attachment conditions. We show that when IDO1 is
expressed by cancer cells, it promotes the generation of one-
carbon units from tryptophan that are used in de novo purine
nucleotide synthesis. Under low serine conditions, tryptophan
can act as an alternative one-carbon source to support prolifer-
ation, and that its combination with dietary serine and glycine
restriction can increase the anti-tumor efficacy of the IDO1 inhib-
itor epacadostat. We also show that tryptophan-derived formate
can be released by cancer cells. Intriguingly, we find that pancre-
atic stellate cells (a key component of the tumor stroma) can
capture this exogenously derived formate and, in similarity to
cancer cells, channel it into de novo nucleotide synthesis.
RESULTS
PDAC cells express IDO1 in a context-dependent
manner
To perform metabolic analyses on cells expressing physiologi-
cally relevant levels of IDO1, we sought to evaluate the expres-
sion of IDO1/Ido1 in pancreatic cancer cells across a range of
in vitro and in vivo contexts (Figure 1A). Direct analysis of pancre-
atic tumor tissue from Pdx1-Cre;LSL-KrasG12D/+;Trp53fl/+ and
Pdx1-Cre;LSL-KrasG12D/+;LSL-Trp53R172H/+ mice showed that
tumors had increased Ido1 expression versus normal pancreas
tissue, and that certain tumors expressed high levels of Ido1 (Fig-
ures 1B and 1C). Compared to genetically engineered mouse
model (GEMM) tumor tissue, tumor-derived primary KPC cells
cultured under normal in vitro conditions displayed undetectable
Ido1 (Figure 1D). Addition of themurine form of the immune cyto-
kine IFNg, a canonical activator of Ido1, increased Ido1 expres-
sion in vitro. As expected, the human form of IFNg did not affect
Ido1 expression in murine cells (Figure 1D).
To assess whether in vivo growth could restore Ido1 expres-
sion, we injected mixed background or pure C57Bl6/J KPC cells
into mice as subcutaneous allografts in three separate experi-
ments. In the first experiment, mixed background primary KPC
cells showed very low Ido1 expression when injected into immu-
nocompromised CD1-nude mice (Figure 1D). In contrast, in the
second experiment, the growth of 3 C57Bl6/J KPC cell lines in
immunocompetent syngeneic mice showed several instances
of strong Ido1 expression for 2 of 3 cell lines (Figure S1A), albeit
with intra-animal variability, as seen with autochthonous KPC
models in Figure 1B. For the third experiment, we implanted
the 3 C57Bl6/J KPC cell lines in immunocompetent (C57Bl6/J)
and immunocompromised (CD-1 nude) mice simultaneously
and directly compared Ido1 expression (using cell line no. 2
in vitro as a western blot control for Ido1 expression) (Figure 1E).
This side-by-side experiment clearly showed a lack of Ido1
expression in immunocompromised mice, but several instances
of robust Ido1 expression in immunocompetent mice, with Ido1
levels in vivo comparable to in vivo growth +IFNg. Overall, these






Figure 1. Tumor expression of Ido1 in KPC PDAC models requires an intact immune system in vivo
(A) Schematic diagram detailing the methods used to analyze Ido1 expression in mouse models of PDAC.
(B andC) Tumors fromPdx1-Cre;KrasG12D/+;Trp53fl/+ andPdx1-Cre;KrasG12D/+;Trp53R172H/+mice and healthy pancreas tissue from non-Cre-expressing isogenic
control mice analyzed by western blots (B) quantified using a Li-Cor infrared scanner (C) (healthy pancreas n = 5, Pdx1-Cre;KrasG12D/+;Trp53fl/+ tumors n = 6,
Pdx1-Cre;KrasG12D/+;Trp53R172H/+ tumors n = 5, p values calculated with unpaired 2-sided t test, bars are SDs).
(D) KPC cell line isolated from a mixed-background Pdx1-Cre;KrasG12D/+;Trp53R172H/+ tumor was either grown in vitro culture (with or without human or mouse
IFNg (1 ng/mL) for 24 h), or subcutaneously injected into the flank of CD1-nude mice to form tumors. Cell and tumor lysates were analyzed for the indicated
proteins.
(E) Three KPC cell lines isolated from C57Bl6/J Pdx1-Cre;KrasG12D/+;Trp53R172H/+ mice were injected into the flanks of C57Bl6/J mice or CD-1-nude mice to form
tumors. Cell and tumor lysates were analyzed for the indicated proteins.
(F) Survival data for human pancreatic cancer patients from TCGA was downloaded from The Human Protein Atlas (https://www.proteinatlas.org/). Log-rank p
value (Mantel-Cox test) was calculated using GraphPad Prism.
(G) The indicated human cell lines were treated with human IFNg (1 ng/mL) for 24 h and analyzed for protein expression.
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Figure 2. IDO1 is also regulated by attachment-independent growth via JAK/STAT signaling
(A) Schematic diagram of the kynurenine pathway.
(B–D) Protein expression was analyzed after 24 h of (B) culture under either normoxic (20%O2) or hypoxic (1%O2) conditions, (C) treatment with rotenone (1 mM)
or vehicle-only control, or (D) culture in media containing either glucose (Glc) (10 mM) or galactose (Gal) (10 mM).
(E and F) Cell lines were cultured in 2D or 3D conditions for 24 h and cell lysates analyzed for protein expression, and (F) band intensity of IDO1 relative to actin
(loading control) was quantified with a Li-Cor infrared scanner (data from n = 4 independent experiments, p value calculated with paired 2-sided t test, bars
are SDs).
(G) CFPAC-1 cells were cultured in 2D or 3D (attachment-independent) conditions for 24 h and treated with epacadostat (1 mM) or vehicle-only control for 16 h
before media (extracellular) kynurenine was analyzed by LC-MS (n = 3 biological replicates, bars are SDs).
(H) CFPAC-1 and HPAF-II cells were cultured in either 2D or 3D conditions for 24 h and then treated for 16 h with JAKi or vehicle-only control (veh.) and/or human
IFNg (1 ng/mL). Cells were then lysed and protein expression analyzed.
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T cells and macrophages (both sources of IFNg secretion; Gao
et al., 2003) infiltrate PDAC tumors (Xu et al., 2020).
To assess IDO1 expression in human cancers, we extracted
data from the metabolic gene rapid visualizer (MERAV; Shaul
et al., 2016). In the pancreas, IDO1 had a similar range of
mRNA expression in healthy tissue compared to cancer cell lines
grown in vitro (Figure S1B). However, pancreatic tumor tissue
had multiple high or very high IDO1-expressing tumors. This
trend was also observed in a variety of other tumors, particularly
in the colon, breast, and cervix. This dataset shows very consis-
tently, and in line with our observations with KPC cells, that IDO1
expression can be elevated in tumor versus healthy tissue, but
that cancer cells grown under normal in vitro culture conditions
(i.e., without IFNg) do not recapitulate the IDO1 expression levels
seen in such tumors. These human data also highlight the poten-
tial intra-tumor variability in IDO1 expression, as seen in KPC tu-
mors (Figures 1E and S1A). Previous work suggests that varia-
tion in cell extrinsic factors (e.g., variation in immune cell4 Molecular Cell 81, 1–13, June 3, 2021infiltration supplying IFNg) and intrinsic factors (e.g., cyclooxyge-
nase-2/interleukin-6 [IL-6] signaling) can contribute to this
variability (Hennequart et al., 2017; Litzenburger et al., 2014).
Analysis of human pancreatic cancer survival data shows that
high IDO1 expression correlates with worse survival (Figure 1F).
Next, we assessed the expression of IDO1 in a panel of human
pancreatic cancer cells. Similar to KPC cells, and as predicted by
the MERAV data, IDO1 expression was very low or undetectable
under normal culture conditions, but the addition of IFNg (human
form) consistently increased IDO1 expression (Figure 1G). Over-
all, these data suggest that IDO1 expression can be upregulated
during tumor formation in an immunocompetent setting.
IDO1 expression can also be regulated by attachment-
independent (AI) growth in vitro
Given the diversity of potential metabolic interactions of the ky-
nurenine pathway (Figure 2A), we sought to investigate whether
immune-independent stimuli could also affect IDO1 expression.
Mitochondrial metabolism is potentially linked to the kynurenine
A
B
Figure 3. Tryptophan-derived one-carbon units are incorporated into serine and purine nucleotides in pancreatic cancer cells
(A and B) CFPAC-1 cells were grown with or without human IFNg (1 ng/mL) or with IFNg and IDO1 inhibitor epacadostat for 24 h (A), or in 2D versus 3D conditions
for 24 h (B), in the presence of 13C11-tryptophan. Intracellular metabolites were analyzed by LC-MS and corrected for natural background
13C abundance. y axis =
(legend continued on next page)
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(Murphy, 2009) and (2) entry of tryptophan-derived carbons into
the TCA cycle via a-ketoadipate. Exposure of PDAC cells to low
oxygen or rotenone—both predicted to affect oxidative phos-
phorylation (OXPHOS) and potentially modulate superoxide
levels—had little impact on IDO1 expression (Figures 2B and
2C). Similarly, the substitution of glucose with galactose (to pro-
mote OXPHOS) did not modulate IDO1 expression (Figure 2D).
Unexpectedly, we found that transferring cells from two-dimen-
sional (2D) monolayer culture to AI 3D growth (without any other
adjustments to culture conditions) caused increased IDO1
expression in BxPC-3, CFPAC-1, HPAF-II, and SU.86.86 cells
(Figures 2E, 2F, S2A, and S2B). This was accompanied by a dra-
matic increase in IDO1-dependent kynurenine pathway activity,
as measured by kynurenine efflux, which was ablated by the
IDO1 inhibitor epacadostat (Figure 2G).
AI growth stimulates IDO1 expression via Janus kinase
-signal transducer and activator of transcription (JAK/
STAT) signaling
While AI growth had a less dramatic impact on IDO1 expression
than IFNg, we sought to establish whether the mechanisms of
these two stimuli were linked or independent. Treatment with
the proteasome inhibitor MG132 (Figure S2C) or with the lyso-
somal inhibitor bafilomycin (Figure S2D) had no effect on IDO1
protein levels. This suggests that the increased IDO1 levels
observed during AI growth were not due to changes in IDO1
degradation via proteasomal or lysosomal systems.
IFNgmediates changes in gene expression through the activa-
tion of the JAK/STAT signaling cascade (Mojic et al., 2017). We
questioned whether AI growth could also activate the JAK/STAT
pathway, leading to increased IDO1 expression. We found that
STAT3 phosphorylation was increased upon AI growth (Figures
1H and S2E), indicating upregulated JAK/STAT pathway activa-
tion. This appeared to be specific to STAT3, as no such increase
was detected for STAT1 (Figures S2F and S2G). Upregulation of
IDO1 protein levels in AI-grown cells was blocked by treatment
witha JAK inhibitor (JAKi) (Figures2HandS2E). These results sug-
gest that whereas IFNg stimulates JAK/STAT signaling involving
both STAT1 and STAT3 activation, AI growth activates only
STAT3, which results in a smaller increase in IDO1 expression.
Given the ability of STAT3 to bind the IDO1 promoter and promote
IDO1 transcription (Sun et al., 2009; Yu et al., 2014), we sought to
confirm the response to AI growth at the mRNA level. qRT-PCR
confirmed that AI growth increased IDO1 transcription
(Figure S2H).
Tryptophan contributes one-carbon units to purine
synthesis in vitro
During the IDO1-dependent metabolism of tryptophan through
the kynurenine pathway, a number of metabolites are formed
that are known to have potentially important roles in cancer
metabolism (Figure 2A). To investigate the production of such13C labeled fraction for the stated isotopologues. Labeled isotopologues are defi
positions of tryptophan-derived carbons are labeled in red in the structural diagr
See Figure S3C for explanation of labeling in acetyl-CoA. n = 3 biological replica
6 Molecular Cell 81, 1–13, June 3, 2021metabolites from tryptophan in cancer cells expressing IDO1,
we cultured cells with IFNg in the presence of 13C11-tryptophan
and performed liquid chromatography mass spectrometry (LC-
MS) analysis. Cells readily took up 13C11-tryptophan, and over
24 h, the cellular tryptophan pool was fully labeled. As expected,
we found a high fraction of labeling in kynurenine (Figures 3A and
S3B). Downstream of kynurenine, a small amount of labeling was
identified in alanine; however, this was a very small fraction.
Tryptophan can be metabolized to acetyl-coenzyme A (CoA)
via three routes: alanine, a-ketoadipate (both of which contribute
to the acetyl group), or purine nucleotide synthesis (which con-
tributes to the purine ring) (Figure S3C). While we detected sub-
stantial labeling in acetyl-CoA, very little labeling was seen in the
TCA cycle (Figures S3A and S3B), illustrating that acetyl-CoA
was predominantly labeled in the purine ring of coenzyme A,
rather than the acetyl group that enters the TCA cycle. In addition
to very low/negligible labeling in the TCA cycle, no kynurenine-
dependent (m+6) labeling was detected in NAD/H or NADP/H.
During the formation of kynurenine from tryptophan, a one-
carbon unit is released as formate. A potential destination for
this formate is to enter the THF cycle. From there, the trypto-
phan-derived carbon could be used in a number of anabolic
pathways, including purine nucleotide synthesis. We found clear
evidence for tryptophan-derived carbons entering purine nucle-
otide biosynthesis (Figures 3A and S3B), indicating that trypto-
phan is a legitimate source of one-carbon units for the THF cycle
in PDAC cells. Another THF-dependent fate for one-carbons is
de novo serine synthesis (by combination with glycine via
SHMT1/2), and we also saw increased labeling of serine from
labeled tryptophan, but this was a small fraction compared to
purines. Yet another THF-dependent destination for one-car-
bons is the re-methylation of homocysteine to methionine,
which, via conversion to S-adenosylmethionine (SAM), can be
used in methylation reactions. Interestingly, we detected a small
but consistent fraction of 13C11-tryptophan-dependent labeling
in methionine, suggesting that tryptophan-derived carbons
may also contribute to SAM synthesis and methylation reactions
(Figure S3D). While the fractional labeling in kynurenine was very
high under all three experimental conditions (Figures 3A and
S3B), analysis of raw peak area data confirmed that the total
levels of kynurenine were dramatically increased by IFNg treat-
ment and decreased by epacadostat, as expected (Figure S3E).
The extent of labeling seen in purines was notable, especially
given that these cells were grown with ample exogenous serine,
a major one-carbon source (medium contained 0.4 mM serine
compared to 0.08 mM tryptophan). Labeling in serine was a
much lower fraction than purines, suggesting that purine labeling
occurs primarily through the direct entry of tryptophan-derived
formate to the THF cycle rather than via serine synthesis.
We confirmed that AI growth was also able to stimulate the
incorporation of tryptophan-derived one-carbon units into purine
nucleotides, finding an increased fraction of labeling in AMP,
ADP, ATP and guanosine triphosphate (GTP) in AI-grown cellsned as mass + n (m+n), where n = number of 13C incorporated. The potential
ams.




(legend on next page)
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treated cells, reflecting the smaller increase in IDO1 expression
caused by AI growth. Overall, these data clearly indicate that it
is possible for IDO1-expressing PDAC cells to use tryptophan
as a substantial source of one-carbon units for purine nucleotide
synthesis.
Tryptophan-derived one-carbon units contribute to
serine and purine synthesis in tumors and support
proliferation when serine is limiting
Next, we investigated whether tryptophan could contribute one-
carbon units to purine synthesis in PDAC tumors in vivo. Given
the potential variability in IDO1 expression in autochthonous
GEMM and KPC allograft tumors (taking into account data
shown in Figures 1B, 1E, and S1A), and to consistently and reli-
ably recapitulate the setting of a IDO1-expressing tumor, we en-
gineered KPC cells to stably express IDO1. Western blot
confirmed that KPC-IDO1 cells expressed lower but comparable
IDO1 levels to IFNg-treated PDAC cell lines (Figure S4A), and
LC-MS analysis confirmed that KPC-IDO1 cells had upregulated
tryptophan-dependent one-carbon metabolism versus KPC-EV
(empty vector) cells (Figure S4B). In line with IDO1 protein
expression, the extent of labeling in purines in KPC-IDO1 cells
was lower but comparable with IFNg treated PDAC cells
in vitro (Figures 3A and S3B). These comparisons demonstrate
that the KPC-IDO1 cells stably express levels of IDO1 compara-
ble to immune-driven IDO1 expression in human cancer cells.
We implanted these cells into syngeneic immunocompetent
mice as subcutaneous allografts (Figure 4A). Once tumors had
formed, mice received a single intraperitoneal injection of
13C11-tryptophan solution, and we assessed the incorporation
of tryptophan-derived carbons using LC-MS at a single time
point (3 h) post-injection.
Despite the inherent difficulty of detecting labeling subsequent
to just a single bolus dose of 13C tracer, which is immediately
further diluted by the 12C pool upon injection and present only
transiently, we found a small but significant increase in the
labeled fraction in serine, ATP, ADP, and guanosine diphosphate
(GDP) (and trends for higher labeling in AMP and guanosine
monophosphate [GMP]) in the tumor tissue of IDO1-expressing
versus EV controls (Figures 4B and S4C). There are different po-
tential routes by which 13C11-tryptophan-derived carbons could
be metabolized into serine and purines within tumors in vivo: (1)
tumor dependent (i.e., primarily via tumor-specific IDO1 expres-
sion), (2) systemicmetabolism dependent (i.e., predominantly viaFigure 4. Tryptophan-derived one-carbon units are incorporated into n
(A) Schematic diagram outlining in vivo 13C11-tryptophan tracing.
(B) KPC cell line 2 (see Figures 1E and S1A) fromC57Bl6/J Pdx1-Cre;KrasG12D/+;Tr
vector control (KPC-EV). Cells were injected into the flanks of C57Bl6/J mice. On
800 mL 120 mM 13C11 tryptophan and harvested after 3 h. The tumor tissue was e
unpaired 2-sided t test, bars are SDs). y axis = 13C labeled fraction for the stated
(C) KPC-IDO1 cells were grown in culture medium with or without serine, with or w
n = 3 biological replicates, bars are SDs.
(D) KPC-IDO1 cells were grown in culture medium with or without serine, with or w
by LC-MS; n = 3 biological replicates, bars are SDs.
(E and F) KPC-IDO1 cells were injected as subcutaneous allografts into BALB/c n
gavage. Mice either received a control diet containing serine and glycine (E) or a
using unpaired 2-sided t test.
8 Molecular Cell 81, 1–13, June 3, 2021IDO1 expressed in healthy tissues, which provides labeled
formate or serine into the circulation, taken up by tumors), or
(3) a combination of these two routes. If labeling was predomi-
nantly via systemicmetabolism, then very similar levels of 13C-la-
beling would be seen in KPC-EV and KPC-IDO1 tumors. As
labeling was higher in KPC-IDO1 tumors, it strongly suggests
that labeling primarily occurs via tumor-specific IDO1
expression.
To further probe the question of tumor versus systemic meta-
bolism, we analyzed serum from 13C11-tryptophan-injected
mice by LC-MS and gas chromatography-MS (GC-MS). There
was no difference in circulating levels of 13C-labeled formate
(or unlabeled formate) between mice with KPC-EV or KPC-
IDO1 tumors (Figure S4D). While we were only able to detect
circulating levels of two purine nucleotides (AMP and GMP),
these did not show any difference in 13C-labeling, and the
same was seen with circulating serine (Figure S4E). These re-
sults indicate that IDO1-expressing tumors can directly metab-
olize tryptophan and incorporate tryptophan-derived carbons
into purine nucleotides in vivo. Relative to in vitro labeling exper-
iments, the level of serine labeling was higher in vivo. We spec-
ulate that compared to cell culture (in which exogenous serine is
ample), there may be increased demands for de novo serine
synthesis (e.g., to support protein synthesis).
Next, we investigatedwhether tryptophan could act as an alter-
native to serine as a one-carbon source to support tumor cell pro-
liferation. Removal of exogenous serine alone or inhibition of IDO1
alone had little impact on the ability of IDO1-expressing KPC cells
to proliferate in vitro. However, the combined inhibition of IDO1
and serine starvation dramatically slowed cell proliferation (Fig-
ure 4C). LC-MSanalysis confirmed that the removal of exogenous
serine increased the contribution of tryptophan to serine and pu-
rine synthesis in an IDO1-dependent manner (Figure 4D).
Given the combined ability of epacadostat and serine restric-
tion to slow the proliferation of IDO-expressing cells in vitro, we
sought to test the effect of this combination on tumor growth. A
key consideration of our in vivo experimental design was to
separate the metabolic and immunomodulatory effects of epa-
cadostat; in other words, in an immunocompetent in vivo setting
the impact of epacadostat on tumor growth would be a function
of metabolic and immunomodulatory changes (Figure S4F). To
eliminate this confounding factor and generate data specifically
reflecting the metabolic impact of IDO1 inhibition in vivo, we
used an immunocompromised mouse model in which epacado-
stat had no impact on tumor growth under normal conditions (Liuucleotides in pancreatic tumors in vivo and can substitute for serine
p53R172H/+ mice were engineered to stably express IDO1 (KPC-IDO1) or empty
ce tumors had formed, the mice were given a single intraperitoneal injection of
xcised and analyzed by LC-MS (EV n = 7, IDO1 n = 7, p values calculated with
isotopologues.
ithout epacadostat (1 mM). The cell number was counted every 24 h for 5 days;
ithout epacadostat (1 mM) for 24 h, and intracellular metabolites were analyzed
ude mice and received vehicle or epacadostat (50 mg/kg twice per day) as oral
matched diet lacking serine and glycine (F). Bars are SDs. p values calculated
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mice is that the endogenous immunological drive for IDO1
expression is lost (as shown in Figures 1E and S1A), so to over-
come this, we used KPC cells stably expressing IDO1 (and EV
controls).
In mice receiving a control diet, IDO1 inhibition had no
impact on tumor growth (Figure 4E), whereas in mice fed a
diet lacking serine and glycine, IDO1 inhibition significantly
slowed tumor growth (Figures 4F and S4G). We noted that
the impact on tumor growth in vivo was not as substantial as
the corresponding in vitro experiment (Figure 4C), possibly re-
flecting that serine levels can be more tightly controlled with
an in vitro experiment.
PDAC cells excrete tryptophan-derived formate
It has been shown that cancer cells can release significant quan-
tities of serine-derived formate (Meiser et al., 2016).We therefore
questioned whether IDO1-expressing PDAC cells would release
formate produced from tryptophan. After culture with 13C11-tryp-
tophan and IFNg, labeled formate was identified by GC-MS in
the spent medium from CFPAC-1 and HPAF-II cells (Figure 5A).
Remarkably, the release of tryptophan-derived formate was
considerably higher than serine-derived formate in CFPAC-1
cells and equivalent in HPAF-II cells. This is a striking result,
given that serine is generally viewed as the dominant one-carbon
source in cancer cells, and that exogenous serine levels (0.4mM)
were five times higher than tryptophan (0.08 mM). In a second
efflux experiment, we equalized the tryptophan and serine con-
centrations (both 0.4mM), and, after normalizing for cell number,
we calculated that tryptophan-derived formate efflux with IFNg
was 13.3 fmol/cell/h in HPAF-II cells and 8.5 fmol/cell/h in
CFPAC-1 cells treated with IFNg, accounting for 50% of total
formate efflux in these cells (29.4 fmol/cell/h in HPAF-II, 14.3
fmol/cell/h in CFPAC-1) (Figure S5A). Previous studies show
that other cancer cell lines have comparable total formate efflux
under normal cell culture conditions (i.e., without IFNg):
HCT116 = 14–16 fmol/cell/h, IMR90 = 10 fmol/cell/h,
HEK293T = 9 fmol/cell/h, and A549 = 0.9 fmol/cell/h (Ducker
et al., 2016; Meiser et al., 2016). Comparison with these studies
emphasizes the substantial contribution of IDO1-dependent
tryptophan metabolism to the synthesis and efflux of formate
by IDO1-expressing PDAC cells.
In the same experiment used for GC-MS analysis of formate
efflux, we used LC-MS to analyze media samples for changes
in tryptophan and kynurenine levels. This analysis shows that
(with IFNg) tryptophan consumption was 13.0 fmol/cell/h in
CFPAC-1 and 32.1 fmol/cell/h in HPAF-II, but much lower
without IFNg (0.64 and 10.4 fmol/cell/h, respectively) (Fig-
ure S5B). Comparison with published levels of serine uptake
(e.g., 22.5 fmol/cell/h for HCT116 and IMR90 cells [Meiser
et al., 2016] and 25.2 fmol/cell/h in HEK293T cells [Ducker
et al., 2016]) indicates that tryptophan uptake is generally lower
than serine under normal culture conditions, but can exceed
serine uptake when IFNg is present. Notably, formate efflux
was 30%–35% less than kynurenine efflux, suggesting that
approximately one-third of formate generated by IDO1 was
used intracellularly, with the remaining two-thirds released
(Figure S5B).Stellate cells take up cancer cell-generated tryptophan-
derived formate and use it for purine synthesis
While we have previously reported on the ability of cancer cells to
efflux formate (Meiser et al., 2016), with implications for cell inva-
sive properties (Meiser et al., 2018) it is unknown whether
formate efflux has any metabolic consequences for the tumor
microenvironment. Spatial analysis of Ido1 expression in the
KPC tumors shown in Figure 1B demonstrated that Ido1 expres-
sion was higher in cancer cells than stromal cells in every tumor
tested (Figure S5C). Publicly available data (The Human Protein
Atlas) shows several examples of human PDAC tumors with
strong IDO1 expression, and that IDO1 is primarily confined to
cancer cells rather than stromal cells (Figure S5D). Given the
dense stromal component of pancreatic tumors, we speculated
that exogenous formate could affect stromal cell metabolism.
To directly test the ability of pancreatic stellate cells to take up
and use exogenous formate, we cultured immortalized mouse
pancreatic stellate cells (ImPSCs) in media supplemented with
13C1-formate. LC-MS revealed that stellate cells were capable
of consuming extracellular formate and incorporating its single
carbon into purines (Figure S5E). To assess whether trypto-
phan-derived formate produced within PDAC cells could be
used in the same way, we used two techniques: (1) conditioned
media transfer and (2) direct co-culture (Figure 5B). To condition
themedium,PDACcellswere grown inmediumcontaining 13C11-
tryptophan, and conditioned medium was collected after 24 h.
Filtered medium was then transferred onto stellate cells before
analysis of the stellate cells by LC-MS. Labeling of purine nucle-
otides and serine was detected in stellate cells given conditioned
medium from IDO1-expressing (+IFNg) PDAC cells (Figure 5C).
Labeling was prevented when the PDAC cells were treated with
epacadostat during the conditioning process. Critically, labeling
was unaffected when epacadostat was added after conditioning
(i.e., while stellate cells were grown with conditioned medium),
indicating that IDO1 activity in the PDAC cells, not the stellate
cells, is critical for stellate cell formate utilization. This was also
found when the experiment was repeated with ImPSC #2 cells
(Figure S5F). To further confirm these findings, we performed
direct co-culture assays. CFPAC-1 cells were co-cultured for
24 h with ImPSC cells engineered to ectopically express GFP.
The co-culture medium contained 13C11-tryptophan and IFNg.
The ImPSC-GFP cells were then separated from the PDAC cells
by fluorescence-activated cell sorting (FACS) and subjected to
LC-MS analysis. Labeling of purine nucleotides was evident in
stellate cells co-cultured with PDAC cells in the presence of
IFNg (Figure 5D). However, with thismore technically challenging
method, the labeled fractionswere generally smaller and labeling
in serine was very similar to background levels. Importantly, la-
beling was lower when IDO1 levels were low (IFNg) or IDO1
was inhibited by treatment with epacadostat (Figure 5D). These
results show that pancreatic stellate cells can consume and
metabolize tryptophan-derived formate that has been released
by PDAC cells in an IDO1-dependent manner (Figure 5E).
DISCUSSION
While serine is thought to be a dominant source of one-carbon





Figure 5. PDAC cells release tryptophan-derived formate, which is consumed by pancreatic stellate cells and incorporated into nucleotides
(A) CFPAC-1 andHPAF-II cells were cultured in 3D for 4 days and then treatedwith IFNg (1 ng/mL) or vehicle-only control in the presence of either unlabeled (12C),
13C11-tryptophan 0.08 mM, or
13C3
15N1-serine 0.4 mM for 24 h. Media samples were analyzed for extracellular formate using GC-MS; n = 3 biological replicates,
bars are SDs. y axis = 13C labeled fraction for the stated isotopologues.
(B) Schematic diagram of the experimental approaches used in (C) and (D).
(C) CFPAC-1 cells were treated with vehicle-only control or human IFNg (1 ng/mL) and epacadostat (Epac., 1 mM) or vehicle-only control in the presence of
unlabeled (12C) or 13C11 tryptophan. Conditionedmediawas collected after 24 h and ImPSCs (immortalized pancreatic stellate cells) were cultured in thismedia or
in non-conditioned treatment-matched media. After 24 h, intracellular metabolites were analyzed by LC-MS; n = 3 biological replicates, bars are SDs.
(D), ImPSC-GFP cells were cultured for 24 h as amonoculture or in co-culture with CFPAC-1 cells. Cells were then treatedwith vehicle-only control or human IFNg
(1 ng/mL) and epacadostat (1 mM) or vehicle-only control in the presence of 13C11 tryptophan for 24 h. Cells were then trypsinized and sorted using FACS for GFP
+
cells and intracellular metabolites were analyzed by LC-MS; n = 3 biological replicates, bars are SDS.
I Illustration of the proposed model.
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the THF cycle in ways that can affect cancer therapy (Kanarek
et al., 2018). Improved understanding of which nutrients and
pathways feed the THF cycle will enhance our ability to deploy
emerging anti-cancer strategies such as dietary serine with-
drawal or serine synthesis inhibition, as well as traditional anti-
folate therapies. The kynurenine pathway has been studied
intensively for its ability to modulate immune cell behavior. In
particular, IDO1 inhibitors have been aggressively explored as
anti-cancer immunotherapies. Results from clinical trials have
so far been mixed, leading to the wider activities of IDO1 being
described as a ‘‘black box,’’ and calls for improved mechanistic
understanding of this enzyme (Garber, 2018). Given the signifi-
cant clinical interest in IDO1, its known role as a metabolic
enzyme, and the widespread engagement in cancer metabolism
research, it is surprising that to date little effort has beenmade to
interrogate the metabolic functions of this enzyme. This is espe-
cially relevant given the potential importance of kynurenine
pathway-derived metabolites for cancer cell metabolism.
While serine is considered the primary source of one-carbon
units in cancer cells, the present study highlights that in IDO1-ex-
pressing cancer cells, tryptophan is potentially a major alterna-
tive source of one-carbons for the THF cycle. Multiple studies
have reported on the ability of a serine- and glycine-deficient
diet to slow tumor growth in preclinical cancer models (Baksh
et al., 2020; LeBoeuf et al., 2020; Maddocks et al., 2013, 2017;
Muthusamy et al., 2020). Interestingly, KPCmodels resist dietary
serine and glycine restriction (Maddocks et al., 2017). Previously
we attributed this solely to the upregulation of de novo serine
synthesis; the present study suggests that utilization of trypto-
phan can substitute for serine as a one-carbon donor, a process
that can be targeted with IDO1 inhibitors such as epacadostat.
The ability of KPC tumors to eventually grow despite serine re-
striction and epacadostat treatment suggests that de novo
serine synthesis does contribute to resistance, but that this takes
longer to initiate than switching to tryptophan.
Overall, these results shed increased light on IDO function,
and suggest that IDO1 could have an important role beyond im-
mune regulation, with the potential to influence one-carbon
metabolism in cancer and stromal cells. We show that in IDO1-
expressing tumors, tryptophan is a legitimate one-carbon source
for the THF cycle. Our data also provide a mechanistic explana-
tion as to why tryptophan has been reported as one of the most
highly depleted interstitial nutrients in PDAC (Sullivan et al.,
2019a). Furthermore, our data show that biological context is
critical for the study of IDO1 function, with standard cell culture
conditions being a poor model. While this study has focused
on pancreatic cancer, human IDO1 expression data suggest
that our findings are relevant across a range of other human can-
cers, particularly colon, breast, cervix, and lung.
Limitations
Further exploration of the link between attachment-independent
growth and STAT3/IDO1 activation (e.g., in the context of metas-
tasis formation) would help to better define the biological rele-
vance of this phenotype to cancer. Our data also illustrate a
wide variability in the expression of IDO1 in vivo. While the liter-
ature suggests that this could be accounted for by cell-intrinsicand -extrinsic factors, a more thorough exploration of what dic-
tates tumor IDO1 expression would be valuable—for example, in
helping to stratify treatment with IDO1 inhibitors. While our short-
term in vivo 13C-tryptophan experiment did show a change in
tumor tryptophan metabolism due to IDO1 expression, a
longer-term analysis (e.g., using constant infusion) would be
required to more accurately quantify the scale of this effect.
While our in vivo tumor growth experiment did show cooperation
between dietary serine and glycine restriction and epacadostat
treatment, this was far less dramatic than the corresponding
in vitro data. Further tumor growth assays are required to more
fully characterize this effect—for example, using immunocompe-
tent models in which the combined metabolic and immunomod-
ulatory effects of IDO1 inhibition are taken into account.
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Materials availability
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fer Agreement.
Data and code availability
The datasets generated in this study will be made publicly available at: https://www.gla.ac.uk/researchinstitutes/cancersciences/
staff/olivermaddocks/#researchdatasets. Uncropped western blots and related data is available at: http://doi.org/10.17632/
2wwd7hrxs3.1
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Cell culture
All the cell lines used in this study were cultured at 37C in 5% CO2 in a humidified incubator. Human cell lines were authenticated
using Promega GenePrint 10 and tested for mycoplasma using Mycoalert (Lonza). AsPC-1 (female), BxPC-3 (female), CFPAC-1
(male), HPAF-II (male), Panc 10.05 (male) & SW 1990 (male) cells were cultured in RPMI (Invitrogen, 31870025) supplemented
with 10% FBS, 1% penicillin-streptomycin, 0.2% amphotericin B and glutamine (2mM). Mouse ImPSC and KPC cell lines were
cultured in DMEM (Invitrogen, 21969035) supplemented with 10% FBS, 1% penicillin-streptomycin, 0.2% amphotericin B and gluta-
mine (2mM). KPC lines were a gift from Jennifer Morton and Saadia Karim (Ximbio, 153474), and were isolated from the tumors of
Pdx1-cre;LSL-KrasG12D/+;LSL-Trp53R172H/+ mice either with a mixed or pure C57Bl6/J background. KPC-IDO1 & KPC-EV cell lines
were made from pure C57Bl6/J KPC cells using the PiggyBac transposon system. ImPSC #1 lines were a gift from Jurre Kamphor-
st(Auciello et al., 2019). ImPSC #2 & #3 lines were isolated from Pdgfratm11(EGFP)Sor mice(Hamilton et al., 2003) (JAX stock #007669).
Mice
All in vivo work was carried out in compliance with the Animals (Scientific Procedures) Act 1986 and the EU Directive 2010 (PPLs
60/4181, 70/8645, 70/8468 and 70/8646) and was sanctioned by the local ethical review process (University of Glasgow).Mus mus-
culus cohorts were housed in a barrier facility proactive in environmental enrichment and maintained on a normal chow diet ad
libitum. Mice were genotyped by Transnetyx (Cordova, Tennessee, USA). The LSL-KrasG12D, Pdx1-cre;LSL-KrasG12D/+;Trp53fl/+
and Pdx1-cre;LSL-KrasG12D/+;LSL-Trp53R172H/+ models/alleles have been described previously(Hingorani et al., 2005; Morton
et al., 2010). Mixed male and female populations were used for each genotype. Cohorts were on a mixed strain background
but all cohorts consisted of litter-matched controls and were killed at a humane clinical end point. For allograft of mixed back-
ground KPC cells, CD-1 Nude (Crl:CD1-Foxn1nu) female mice were used (Charles River, 7 weeks old). For allograft of pure
C57Bl6/J KPC cells, C57Bl6/J female mice were used (Charles River, 7 weeks old). For tumor growth experiment (Figures 4E
and 4F) BALB/c Nude female mice (CAnN.Cg-Foxn1nu/Crl) were used (Charles River, 8 weeks old).
METHOD DETAILS
Extraction of ImPSC cell lines
ImPSC #1 cells were a gift from Jurre Kamphorst(Auciello et al., 2019). Briefly, healthy pancreas tissue extracted fromC57Bl6/J mice
wasminced and digested for 20mins at 37Cwith 0.1%DNase (Roche), 0.05%Collagenase P (Roche) and 0.02%Pronase (Roche) in
Gey’s balanced salt solution (GBSS; Sigma Aldrich). The tissuewas then titurated until the large pieceswere no longer visible, passed
through a 100mmfilter and washed with GBSS. The cells were then pelleted and resuspended in 9.5ml GBSSwith 0.3%BSA and 8ml
Nycodenz solution (Sigma Aldrich). The cell suspension was layered beneath GBSS containing 0.3%BSA, and centrifuged at 1400 x
g for 20 min at 4C. Stellate cells were harvested from the interface of the Nycodenz solution at the bottom and the aqueous solution
at the top. The PSCs isolated were then washed with GBSS and resuspended in DMEM with 10% characterized FBS (HyClone),
100 U/ml penicillin and 100m/ml streptomycin (Invitrogen). The cells were immortalized with the pRetro. Super.shARF retroviral
plasmid (provided by the Karen Vousden lab) and selected with blasticidin (4mM).
ImPSC #2 & #3 lines were isolated using a very similar protocol as ImPSC #1with someminor differences detailed below. Pancreas
tissue was extracted from Pdgfratm11(EGFP)Sor mice(Hamilton et al., 2003) (JAX stock #007669), minced with a scalpel and digested
with 0.1% DNase I (Thermo Fisher Scientific, 90083) and 0.05% collagenase P (Roche, 11 213 865 001) in GBSS for 30mins at 37C.
The solution was then passed through a 100mm filter, washed with GBSS, pelleted and resuspended in 6ml GBSS containing 0.3%
BSA. The cell suspension was then mixed with 8ml Histodenz solution (43.75% in GBSS), layered beneath GBSS containing 0.3%
BSA, and centrifuged at 1400 x g for 20mins at 4C. Stellate cells were harvested from the interface of the Histodenz solution at thee3 Molecular Cell 81, 1–13.e1–e7, June 3, 2021
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ing 10% FBS, 1% penicillin- streptomycin, 0.2% amphotericin B and glutamine (2mM). After culture was established, fibroblasts ex-
pressing GFP were isolated via FACS and immortalized spontaneously.
ImPSC #1 cells stably expressing GFP (ImPSC-GFP cells) were generated by the PiggyBac transposon system. Briefly, 5 3 104
ImPSC #1 cells were seeded in a 6-well plate. 24h after seeding, cells were transfected using Lipofectamine 3000 (Thermo Fisher
Scientific, LS3000008) with 1.5mg Super piggyBac Transposase expression vector (Cambridge Biosciences, PB210PA-1) and
0.6mg PB-GFP PB-CMV-MCS-EF1-GreenPuro (Cambridge Biosciences, PB513B-1). 24h after transfection, cells were selected in
5mg/ml puromycin for 48h, until puromycin sensitive control cells treated in parallel were dead.
Production of KPC-EV and KPC-IDO1 cell lines
Pure C57Bl6/J KPC cells stably expressing IDO1-RFP or RFP only (empty vector control) were generated using the piggyback sys-
tem. Briefly, human IDO1 cDNA was cloned into the PB-RFP PB-CMV-MCS-EF1-RedPuro cDNA cloning and expression vector us-
ing XbaI and EcoRI. Successful cloning was confirmed by full sequencing of the insert. 2.5 3 105 pure C57Bl6/J KPC cells were
seeded in a 6-well plate. 24h after seeding cells were transfected using Lipofectamine 3000 (Thermo Fisher Scientific,
LS3000008) with 1.5mg Super piggyBac Transposase expression vector (Cambridge Biosciences, PB210PA-1) and 0.6mg of either
PB-RFP PB-CMV-IDO1-EF1-RedPuro (IDO1 stable expression) or PB-RFP PB-CMV-MCS-EF1-RedPuro (empty vector control,
Cambridge Biosciences, PB514B-2). 24h after transfection, cells were selected in 5mg/ml puromycin for 48h, until puromycin sensi-
tive control cells treated in parallel were dead. To identify high expressers of IDO1, cells were grown as clones and validated for
expression by immunoblotting.
Hypoxia experiments
Cells were seeded and allowed to grow for 48h to 80% confluence under normal tissue culture conditions. Cells were then trans-
ferred to a humidified Whitley H35 hypoxystation (Don Whitley Scientific) controlled by a hypoxic gas mixer at 37C with 1% O2, 5%
CO2, and 94% N2 for 24h prior to lysis following standard RIPA lysis protocol (see below)
Attachment independent 3D growth experiments
1 3 106 cells were seeded in ultra-low attachment plates (Corning Costar, CLS3471) for 48h. For treatments, cells were collected,
centrifuged at 50 x g for 5mins and washed in PBS. Cells were then resuspended in 2ml of treatment medium and transferred
back into ultra-low attachment plates for indicated treatment times.
Conditioned medium experiments
9 3 106 HPAF-II or CFPAC-1 cells were seeded in 10cm dishes in their normal growth media. Experimental media for conditioning
were formulated lacking tryptophan and supplemented with the stated concentrations of 13C11-tryptophan. After 48h in culture, cells
were washed in PBS and media for conditioning was added. After 48h, conditioned medium was collected and passed through a
0.45mm filter to remove cells. Conditioned medium was stored at 20C prior to use.
Co-culture experiments
53 105 ImPSC-GFP cells were seeded either alone or with 13 104 CFPAC-1 cells in 6-well plates. Experimental media was formu-
lated lacking tryptophan and supplemented with 0.4mM 13C11 tryptophan. After 24h in culture, cells were washed in PBS and media
containing human IFNg (1ng/ml) or vehicle only control and/or epacadostat (1mM) or vehicle only control was added. After 24h, cells
were detached rypsinizationion, washed in PBS and resuspended to a concentration of 13 107 cells/ml in cold supplemented PBS
(PBS + 3%FBS, 5mM glucose, MEMAmino Acids (Life Technologies, 11130-036) &MEMNEAA (Life technologies, 11140-035)). The
cell suspensions were then passed through a 70mm mesh (Fisher Scientific, PRN-020-030V) to ensure a single-cell suspension and
subjected to fluorescence-activated cell sorting (FACS) using an Aria sorter Z6001 (BD Biosciences) to separate GFP-positive cells
from unlabelled cells. The resultant cell suspension was centrifuged at 300 x g for 5mins and the pellet was resuspended in ice-cold
lysis solvent. Using the cell counts obtained from FACS, the volume of lysis solvent was normalized to 2 3 106 cells per ml. Subse-
quent isolation of metabolites for LCMS was performed as below.
RNA extraction, reverse transcription, and expression analysis
The extraction and purification of total RNA was performed using the RNAeasy purification Kit (QIAGEN) combined with RNase-
Free DNase (QIAGEN) treatment according to the manufacturer’s protocol. RNA concentration and quality was determined using
the NanoDrop 2000 spectrophotometer before downstream processing. Reverse transcription of isolated RNA was performed us-
ing the High Capacity cDNA Kit (Applied Biosystem) according to the manufacturer’s instructions. For expression analysis cDNA
was diluted in DNase- and RNase-free water. qRT-PCR was performed on a CFX96 Touch Real-Time PCR Detection System in 96-
well plates. cDNA was added to Brilliant III Ultra-Fast SYBR Green QPCR Master Mix (Agilent) and primers (1 mM final concen-
tration) in a total reaction volume of 10 mL. qRT-PCR thermal program was carried out by an initial denaturation/polymerase
activation step at 95C for 10 minutes followed by 40 cycles of amplification (95C for 15 s and 60C for 45 s) and melting curve.
Fluorescent signal was detected at the end of every amplification step and continuously during the melting curve. AmplificationMolecular Cell 81, 1–13.e1–e7, June 3, 2021 e4
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and ACTN. The following primers we used: IDO1 (Fw: 50- CTCAGCATTGATCATCTCAC; Rev: 50- AAGACACAGTCTGCATAAAC),
ACTIN (Fw: 50- CCAACCGCGAGAAGATGA; Rev: 50- CCAGAGGCGTACAGGGATAG), GAPDH (Fw: 50- AGCCACATCGCTCAGAC
AC; Rev: 50- GCCCAATACGACCAAATC).
RNA-Scope in situ hybridization and Immunohistochemistry
Ido1 RNA expression across tissue sections was quantified by in situ hybridization (ISH) as described below. In order to define which
regions of the tissue sections were cancer cells and which were stromal cells we stained contiguous sections for the tumor cell
marker EpCAM (Anti-EpCAM antibody, Abcam ab71916) by immunohistochemistry (IHC).
Tumor tissue samples were fixed in 10% neutral buffered formalin then embedded in paraffin to produce a formalin fixed paraffin
embedded (FFPE) block. Prior to staining 4mm sections were heated in an oven at 60C for 2 hours. Sections for EpCAM IHC staining
were loaded into an Agilent PT module and dewaxing/epitope retrieval took place at 97C for 20 minutes using Target Retrieval So-
lution, high pH (Agilent, Denmark). After epitope retrieval all sections were rinsed in flex wash buffer (Agilent, Denmark) prior to being
loaded onto the autostainer. The sections then underwent peroxidase blocking (Agilent, Denmark) for 5 minutes, washed with flex
buffer before application of primary antibody at a previously optimized dilution (1/1500) for 40 minutes. The sections were then
washed with flex wash buffer before application of appropriate secondary antibody for 30 minutes (Rabbit EnVision, Agilent, UK).
Sections were rinsed with flex wash buffer applying Liquid DAB (Agilent, UK) for 10minutes. The sections were then washed in water,
counterstained with hematoxylin z and coverslipped using DPX mountant (CellPath, UK).
ISH detection for Ido1 (product code 315978) and PPIB (product code 313918) both from Advanced Cell Diagnostics (Hayward,
CA) mRNAwas performed using RNA-Scope 2.5 LS (Brown) detection kit (Advanced Cell Diagnostics, Hayward, CA). This technique
was performed on a Leica Bond Rx autostainer strictly adhering to themanufacturer’s instructions. Slides were digitally imaged using
a Leica Aperio AT2 (Leica Biosystems), full cross section digital images were uploaded to HALOSoftware v3 (Indica Labs). Regions of
cancer cells and stroma were defined based on EpCAM staining and Ido1 RNA ISH signals were quantified in these regions across
the full cross section.
Survival analysis
Clinical and normalized gene expression (FPKM) data of TCGA-PAAD dataset were obtained from the Human Protein Atlas (https://
www.proteinatlas.org/). The expression cut-off was calculated on the Human Protein Atlas web portal and used for Kaplan-Meier
curve plotting using GraphPad Prism Software v9. Survival analysis was performed by using the Mantel-Cox log-rank test.
Western blotting
Protein was extracted from whole cells by lysis in RIPA buffer (Thermo Fisher Scientific, 89900) supplemented with protease and
phosphate inhibitor cocktail (Thermo Fisher Scientific, A32959). For cells grown in ultra-low attachment plates, cells were collected
by centrifugation at 50 x g for 5mins, washed in PBS and resuspended in 100mL RIPA lysis buffer. Cells were left to lyse on ice for
10mins and then homogenized by pipetting. For adherent cells, cells were washed in PBS and lysed in 200mL RIPA lysis buffer on
ice in situ, collected using a cell scraper and homogenized by pipetting. Tissue samples were snap-frozen and stored at 80C.
Frozen samples were weighed before lysis to ensure a minimum sample size of 20mg. Samples were homogenized in 2ml RIPA lysis
buffer using a TissueLyser II (QIAGEN). Lysates were cleared by centrifugation at 12,000 x g for 15mins at 4C. Supernatants were
collected and total protein content quantified by BCA assay (Thermo Fisher Scientific, 23227). Lysates were normalized by total pro-
tein content and prepared for western blotting with the addition of 4X Bolt LDS Sample Buffer (+ 355mM b-mercaptoethanol) and
heated to 95C for 10mins. Lysates (25mg) were resolved on Bolt 4%–12% bis-tris plus pre-cast gels (Thermo Fisher Scientific,
NW04122BOX & NW04125BOX) using Bolt MOPS SDS Running Buffer running buffer (Thermo Fisher Scientific, B0001) and trans-
ferred to nitrocellulose membranes. When total protein staining was performed, it was done prior to blocking using Revert Total Pro-
tein Stain (LI-COR, 926-11010). Membraneswere blocked for 1 hour usingOdysseyBlocking Buffer (TBS) (LI-COR, 927-50000) and
incubated overnight at 4Cwith primary antibodies. All primary antibodies were diluted in Odyssey Blocking Buffer at a concentra-
tion of 1:1000, except actin, which was used at 1:10,000. Membranes were washed three times in TBS + 1% TWEEN 20 and incu-
bated with secondary antibodies (1:10,000) for 1h at room temperature. Fluorescence intensity was captured and quantified using a
LI-COR Odyssey Fc Imaging System with Image Studio software (version 5.2). See Key resources table for list of antibodies.
In vivo models
LSL-KrasG12D/+, Pdx1-cre;LSL-KrasG12D/+;Trp53fl/+ and Pdx1-cre;LSL-KrasG12D/+;LSL-Trp53R172H/+ mice were allowed to develop
tumors, killed at humane clinical endpoint and tumors removed for analysis. Pancreas tissue from healthy non-cre-expressing litter-
mates were used as controls.
For allograft experiments assessing Ido1 expression in vivo (Figure 1): three separate C57Bl6/J KPC primary cell lines were im-
planted by bilateral subcutaneous injections (2 3 106 cells per injection) into female C57Bl6/J or female Crl:CD1-Foxn1nu (CD1-
Nude) mice. Mixed background KPC cells were implanted by unilateral subcutaneous injections (2 3 106 cells per flank) into
Crl:CD1-Foxn1nu (CD1-Nude) female mice. Mice were monitored daily until they reached clinical end point or tumor size reached
300mm3.e5 Molecular Cell 81, 1–13.e1–e7, June 3, 2021
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(described above) were implanted by unilateral subcutaneous injections (2 3 106 cells per injection) into female pure C57Bl6/J
mice and allowed to form tumors of 300-500mm2. For 13C11-tryptophan tracing mice were fasted for 3h and then received an intra-
peritoneal injection of 800ml of 120mM 13C Tryptophan (Cambridge Isotope Laboratories). 3h after injection, mice were killed and
tumors removed for LCMS analysis.
For allograft experiment assessing tumor growth (Figures 4E and 4F): KPC-IDO1 cells were implanted by unilateral subcutaneous
injections (1 3 106 cells per injection) into female BALB/c nude mice. One day after cell were implanted mice were transferred to a
control diet (containing serine and glycine) or a matched diet lacking serine and glycine as described previously(Maddocks et al.,
2017). After 4 days on diet mice received vehicle only (0.5% hydroxypropylmethylcellulose, 0.25% tween-20 (both Sigma) in water,
or 50mg/kg of epacadostat by oral gavage twice a day. Tumors were measured three times per week by caliper, and volumes were
calculated using the formula: volume = (length x width2) / 2. On reaching the maximum permitted tumor size (tumor length or widthR
15mm) or if tumors became ulcerated, mice were humanely killed.
LCMS for steady-state metabolite measurements
Metabolomics experiments were performed as described previously(Maddocks et al., 2017). Cells were seeded into 6-well plates in
complete medium and allowed to grow to80% confluence. Cells were washed with PBS and the relevant experimental media were
added for the stated times. Duplicate wells were used for cell counting: cell counts (2D cells) or protein concentration (3D cells BCA
assay) were used to normalize the volume of lysis solvent prior to metabolite extractions (1 3 106 cells per ml). For 2D grown cells,
cells were washed quickly in PBS, then ice-cold lysis solvent (Methanol 50%, acetonitrile 30%, water 20%) was added and cells
scraped on ice. For 3D grown cells, cells were transferred to 15ml falcon tubes and centrifuged at 50 x g for 5 minutes. The super-
natant was removed and the cell pellet was washed in PBS and centrifuged again. The supernatant was removed and the cell pellet
resuspended in ice-cold lysis solvent. Lysates were transferred to 1.5ml tubes on ice, vortexed, then centrifuged at 18,000 x g at 4C
for 10mins. Supernatants were collected and stored at 80C for LCMS analysis. Tissue samples were snap-frozen and stored at
80C. Frozen samples were weighed before lysis. Samples were homogenized in 2ml ice cold lysis solvent using a TissueLyser
II (QIAGEN). Lysates were then cleared of protein by centrifugation at 18,000 x g for 10mins at 4C and then normalized to 10mg/
mL with lysis buffer based on original tissue mass.
Sample analysis was performed using an LCMS platform consisting of an Accela 600 LC system and an Exactive mass spectrom-
eter (Thermo Scientific). A Sequant ZIC-pHILIC column (4.6mm x 150mm, 3.5 mm) (Merck) was used to separate themetabolites with
themobile phasemixed by A = 0.1% (v/v) formic acid in water and B = 0.1% (v/v) formic acid in acetonitrile. A gradient program start-
ing at 20%of A and linearly increasing to 80%at 30min was used followed bywashing (92%of A for 5mins) and re-equilibration (20%
of A for 10min) steps. The total run time of themethod was 45min. The LC streamwas desolvated and ionised in the HESI probe. The
Exactivemass spectrometer was operated in full scanmode over amass range of 70–1,200m/z at a resolution of 50,000 with polarity
switching. The LCMS raw data was converted into mzML files by using ProteoWizard and imported to MZMine 2.10 for peak extrac-
tion and sample alignment. A house-made database including all possible 13C and 15N isotopicm/z values of the relevantmetabolites
was used for the assignment of LCMS signals. Finally the peak areas were used for comparative quantification.
GCMS for formate analysis
Gas chromatography-mass spectrometry (GCMS) (Agilent) was used to quantify formate, as described previously(Meiser et al.,
2016). 40mL of sample was added to 20mL of the internal standard d2-formate (50 mM), 50mL pyridine, 10ml NaOH (1N) and 5mL benzyl
alcohol. While vortexing, 20 mL of methyl choroformate was added to this mixture for derivatisation. 100mL methyl tertiary butyl ether
(MTBE) and 200mL H2O were then added, and the samples subsequently vortexed for 10 s and centrifuged for 10mins at maximum
speed. The apolar phase was then transferred to a GC-vial and capped. Standards and blank samples (water) were prepared in the
same manner and analyzed with the experimental samples to subtract the background and validate the quantification. MassHunter
Quantitative analysis software (version B.06.00 – Agilent Technologies) was used to extract and process the peak areas for formate,
d2-formate and
13C formate. After correction for background signals, quantification was performed by comparing the peak area of
formate (m/z of 136) and of 13C formate (m/z of 137) against that of d2-formate (m/z of 138).
Carbon-13 (13C) labeling of metabolites
Experimental media were formulated lacking tryptophan or serine and supplemented with the stated concentrations of 13C11-tryp-
tophan (Cambridge Isotope Laboratories Inc., CLM-4290-H-PK), 13C3
15N1-serine (Cambridge Isotope Laboratories Inc., CNLM-474-
H-PK) or 13C1-formate (Cambridge Isotope Laboratories Inc., CLM-1284-PK). The same basic protocol was used as for steady state
metabolite measurements (see above). Cell culture, harvest, metabolite extraction and analysis by LCMS was performed as
described above. Labeled isotopologues were defined as mass + n (m+n), where n = number of 13C incorporated. The unlabelled
form is defined as m+0 (i.e., zero 13C present). To correct data for natural (background) 13C abundance we used unlabelled controls
(i.e., complete mediumwithout 13C tracer present) and used the 13C peak areas detected in these samples as empirical 13C baselines
which were subtracted from experimental samples.
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For simplicity we have presented the sum of the 13C labeled fraction for m+n peaks detected above baseline and define these in the x
axis of each bar chart. Matched plots where each isotopologue is plotted separately are presented in supplemental data.
QUANTIFICATION AND STATISTICAL ANALYSIS
Statistical analysis for Figures 4E and 4F was calculated using Microsoft Excel for Mac (v16.43), all other statistical analyses were
calculated usingGraphPadPrismSoftware v9. For in vivo experiments the numbers ofmice are shown in each Figure / Figure Legend.
For statistical comparisons of groups of mice (e.g., for tumor protein expression [Figure 1C] or tumor growth [Figures 4E and 4F])
unpaired 2-sided t tests were performed. For statistical analysis of protein expression by western blot (Figure 1C) single blots
were performed on multiple independent experiments (n = 3-4), as defined in Figures / Figure Legends. For statistical comparisons
of protein expression in 2D and 3D growth conditions in vitro, single blots from n = 3-4 independent experiments were quantified and
compared using paired 2-sided t tests (Figures 2F and S2B). For comparison of RNA-Scope (cancer versus stromal cell IDO1 expres-
sion, [Figure S5C]) a paired 2-sided t test was used. For in vitro mass spectrometry experiments n = 3 biological replicates – corre-
sponding to three separate wells of cells – were used throughout. Error bars are Standard Deviation (SD), a descriptive measure of
variability.e7 Molecular Cell 81, 1–13.e1–e7, June 3, 2021
